Ahmad Tahmasebi-Ghorrabi, Amal Saki Malehi, Amin Torabipour, Amir Hosseinipour, Mohadeseh Davodian, Arman Shahriari
{"title":"糖尿病足溃疡的疾病成本分析:伊朗西南部基于患病率的方法。","authors":"Ahmad Tahmasebi-Ghorrabi, Amal Saki Malehi, Amin Torabipour, Amir Hosseinipour, Mohadeseh Davodian, Arman Shahriari","doi":"10.47176/mjiri.39.1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Diabetic foot ulcer (DFU) is a destructive complication of diabetes that imposes a significant economic burden on patients and the health system. This study was conducted to estimate and influence factors on DFU costs in Ahvaz, Iran.</p><p><strong>Methods: </strong>This study was a cross-sectional study in 2017 among 213 DFU patients referred to Razi Hospital in Ahvaz, Iran. A cost of illness checklist was used to collect information. After calculating the costs, to analyze the effect of variables on the change of costs, regression analysis was used in the generalized linear method with gamma distribution. Also, based on the percentage of changes in cost items in 5 years, the costs of DFU until 2042 were estimated. Data analysis was done using descriptive and analytical tests (gamma regression) in SPSS Version 26 software.</p><p><strong>Results: </strong>The total costs of each patient in the year were 319,885,040 Rials ($7616.31). Direct medical costs were 280,539,930 Rials ($6679.52) (87.7%), indirect medical costs were 5,670,550 Rials ($135.01) (1.77%), and indirect costs were 3,3674,560 Rials ($801.78) (10.53%). Based on the estimate, annual DFU cost items and total costs will increase by 32 and 258.3 times for each patient in 2042, respectively. Regression analysis showed that type of insurance, presence of infection, hospitalization, degree of wound, duration of wound, family history, and employment status are influential factors in changes in DFU costs.</p><p><strong>Conclusion: </strong>DFU treatment costs are a substantial financial burden for patients, and these costs are increasing. Controlling the factors affecting the costs during the treatment process of this disease will reduce the financial burden on the patients.</p>","PeriodicalId":18361,"journal":{"name":"Medical Journal of the Islamic Republic of Iran","volume":"39 ","pages":"1"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12138731/pdf/","citationCount":"0","resultStr":"{\"title\":\"Cost-of-Illness Analysis of Diabetic Foot Ulcer: A Prevalence-Based Approach in Southwest of Iran.\",\"authors\":\"Ahmad Tahmasebi-Ghorrabi, Amal Saki Malehi, Amin Torabipour, Amir Hosseinipour, Mohadeseh Davodian, Arman Shahriari\",\"doi\":\"10.47176/mjiri.39.1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Diabetic foot ulcer (DFU) is a destructive complication of diabetes that imposes a significant economic burden on patients and the health system. This study was conducted to estimate and influence factors on DFU costs in Ahvaz, Iran.</p><p><strong>Methods: </strong>This study was a cross-sectional study in 2017 among 213 DFU patients referred to Razi Hospital in Ahvaz, Iran. A cost of illness checklist was used to collect information. After calculating the costs, to analyze the effect of variables on the change of costs, regression analysis was used in the generalized linear method with gamma distribution. Also, based on the percentage of changes in cost items in 5 years, the costs of DFU until 2042 were estimated. Data analysis was done using descriptive and analytical tests (gamma regression) in SPSS Version 26 software.</p><p><strong>Results: </strong>The total costs of each patient in the year were 319,885,040 Rials ($7616.31). Direct medical costs were 280,539,930 Rials ($6679.52) (87.7%), indirect medical costs were 5,670,550 Rials ($135.01) (1.77%), and indirect costs were 3,3674,560 Rials ($801.78) (10.53%). Based on the estimate, annual DFU cost items and total costs will increase by 32 and 258.3 times for each patient in 2042, respectively. Regression analysis showed that type of insurance, presence of infection, hospitalization, degree of wound, duration of wound, family history, and employment status are influential factors in changes in DFU costs.</p><p><strong>Conclusion: </strong>DFU treatment costs are a substantial financial burden for patients, and these costs are increasing. Controlling the factors affecting the costs during the treatment process of this disease will reduce the financial burden on the patients.</p>\",\"PeriodicalId\":18361,\"journal\":{\"name\":\"Medical Journal of the Islamic Republic of Iran\",\"volume\":\"39 \",\"pages\":\"1\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12138731/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Journal of the Islamic Republic of Iran\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.47176/mjiri.39.1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Journal of the Islamic Republic of Iran","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47176/mjiri.39.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
背景:糖尿病足溃疡(DFU)是糖尿病的一种破坏性并发症,给患者和卫生系统带来了巨大的经济负担。本研究旨在评估伊朗阿瓦士地区DFU成本的影响因素。方法:本研究是一项2017年在伊朗阿瓦士Razi医院转诊的213例DFU患者的横断面研究。使用疾病费用清单收集信息。在计算成本之后,为了分析变量对成本变化的影响,采用广义线性方法进行回归分析。此外,根据5年内费用项目变化的百分比,估计了到2042年的DFU费用。在SPSS Version 26软件中使用描述性和分析性检验(gamma回归)进行数据分析。结果:该年度每位患者的总费用为319,885,040里亚尔(7616.31美元)。直接医疗费用为280,539,930里亚尔(6679.52美元)(87.7%),间接医疗费用为5,670,550里亚尔(135.01美元)(1.77%),间接费用为3,3674,560里亚尔(801.78美元)(10.53%)。据此估算,2042年每位患者年度DFU费用项目和总费用将分别增加32倍和258.3倍。回归分析显示,保险类型、感染情况、住院情况、伤口程度、伤口持续时间、家族史和就业状况是影响DFU费用变化的因素。结论:DFU治疗费用是患者的重大经济负担,且费用呈上升趋势。控制本病治疗过程中影响费用的因素,将减轻患者的经济负担。
Cost-of-Illness Analysis of Diabetic Foot Ulcer: A Prevalence-Based Approach in Southwest of Iran.
Background: Diabetic foot ulcer (DFU) is a destructive complication of diabetes that imposes a significant economic burden on patients and the health system. This study was conducted to estimate and influence factors on DFU costs in Ahvaz, Iran.
Methods: This study was a cross-sectional study in 2017 among 213 DFU patients referred to Razi Hospital in Ahvaz, Iran. A cost of illness checklist was used to collect information. After calculating the costs, to analyze the effect of variables on the change of costs, regression analysis was used in the generalized linear method with gamma distribution. Also, based on the percentage of changes in cost items in 5 years, the costs of DFU until 2042 were estimated. Data analysis was done using descriptive and analytical tests (gamma regression) in SPSS Version 26 software.
Results: The total costs of each patient in the year were 319,885,040 Rials ($7616.31). Direct medical costs were 280,539,930 Rials ($6679.52) (87.7%), indirect medical costs were 5,670,550 Rials ($135.01) (1.77%), and indirect costs were 3,3674,560 Rials ($801.78) (10.53%). Based on the estimate, annual DFU cost items and total costs will increase by 32 and 258.3 times for each patient in 2042, respectively. Regression analysis showed that type of insurance, presence of infection, hospitalization, degree of wound, duration of wound, family history, and employment status are influential factors in changes in DFU costs.
Conclusion: DFU treatment costs are a substantial financial burden for patients, and these costs are increasing. Controlling the factors affecting the costs during the treatment process of this disease will reduce the financial burden on the patients.